Goldstein Advisors’s AbbVie ABBV Stock Holding History

Goldstein Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$994K	Buy	3,951 +251	+7%	+$54K	0.09%	83
2026 Q1	$805K	Buy	3,700 +142	+4%	+$31.5K	0.09%	77
2025 Q4	$813K	Buy	3,558 +321	+10%	+$73.1K	0.09%	78
2025 Q3	$749K	Sell	3,237 -115	-3%	-$23.4K	0.09%	78
2025 Q2	$622K	Sell	3,352 -2,124	-39%	-$395K	0.08%	78
2025 Q1	$1.15M	Buy	5,476 +156	+3%	+$30.3K	0.17%	49
2024 Q4	$945K	Hold	5,320	–	–	0.14%	58
2024 Q3	$1.05M	Buy	5,320 +186	+4%	+$34.7K	0.16%	50
2024 Q2	$881K	Buy	5,134 +120	+2%	+$19.9K	0.15%	52
2024 Q1	$913K	Buy	5,014 +30	+0.6%	+$5.17K	0.16%	53
2023 Q4	$772K	Buy	4,984 +138	+3%	+$20.1K	0.13%	82
2023 Q3	$722K	Buy	4,846 +514	+12%	+$75.5K	0.15%	55
2023 Q2	$584K	Sell	4,332 -494	-10%	-$72.4K	0.12%	67
2023 Q1	$769K	Sell	4,826 -444	-8%	-$67.9K	0.17%	56
2022 Q4	$852K	Buy	+5,270	New	+$808K	0.21%	51

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldstein Advisors's ABBV Position: Q2 2026 in Review

Goldstein Advisors increased its AbbVie (ABBV) stake by 6.8% in Q2 2026, buying an estimated $54K and bringing the position to 3,951 shares worth $994K. The position accounts for 0.09% of the portfolio, ranked #83.

Goldstein Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.15M in Q1 2025. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Goldstein Advisors held 3,951 shares of AbbVie worth $994K as of Q2 2026.
Goldstein Advisors bought 251 AbbVie shares in Q2 2026, an estimated $54K.
AbbVie made up 0.09% of Goldstein Advisors's portfolio in Q2 2026, its #83 holding.
Goldstein Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
Goldstein Advisors's AbbVie position peaked at $1.15M in Q1 2025.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Goldstein Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.